Qnexa May Get Staged Launch After No Vote From Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety concerns and a large market potential for Vivus's obesity drug combine to produce an advisory panel recommendation that leaves FDA "a little surprised."